BIO:ON Insight #9 · Jul 19, 2026
The trial "worked" — so why did nothing change?
Biogen takes its tau drug into Phase 3 despite missing the primary endpoint, the FDA resumes publishing drug rejection letters, and IQVIA data confirms Foundayo's slow start. Why do clinical success and market success keep diverging?
What I learned this week
If I had to sum up this week in one line: clinical data is a starting point, not a conclusion. Headlines always end in "success" or "failure," but there's a lot more going on in between. Reading that in-between together is what this newsletter tries to do every week. See you next issue. 🙏
Yaehyun Lee · Quoted from the Editor's Insight I wrote for this issue.
Stories in this issue
- Clinical Trials
Biogen's tau-targeting diranersen: Phase 2 data at AAIC
Biogendiranersen
- FDA Approvals
FDA resumes publishing complete response letters
US FDA
- Market Trends
Foundayo prescriptions: delayed PBM listings behind the slow start
Eli LillyFoundayo
AI summary
- 1Biogen's tau-targeting Alzheimer's drug diranersen is moving to Phase 3 despite missing its primary endpoint.
- 2The FDA resumed publishing complete response letters (CRLs) that reject new drugs.
- 3IQVIA prescription data showed insurance formularies, not science, deciding Foundayo's market share.
Relevant rolesRegulatory affairsMarket accessInvestment & IR
Summary and tags generated by AI from the issue text.
References
- 1.Biogen's tau drug diranersen Phase 2 data at AAIC 2026 (opens in a new tab)
BioSpace / Investing.com, Jul 14, 2026
- 2.FDA resumes publishing complete response letters (opens in a new tab)
Fierce Biotech, Jul 14, 2026
- 3.Foundayo IQVIA prescription tracker — PBM delays behind the slow start (opens in a new tab)
Fierce Pharma, Jul 17, 2026
Related insights
Other issues covering the same companies, drugs or topics